NAD supplement dosage: what human trials actually tested

There is no single trial-defined dose for every NAD product

A search for an NAD supplement dose often produces one neat number. The research is less interchangeable. Nicotinamide riboside, or NR, and nicotinamide mononucleotide, or NMN, are NAD-related precursors; an oral precursor trial is not a dose-finding study for an NAD+ injection. Even two oral products need the ingredient, formulation and serving size identified before their amounts become useful to compare.

The more important question is what the amount achieved. Raising a blood marker, improving a metabolic measurement and relieving a symptom are separate results. A quantity selected for a research protocol cannot answer all three simply because it appears on a retail label.

An eight-week NR trial tested several amounts

Conze and colleagues randomized 140 otherwise healthy adults with overweight to placebo or 100, 300 or 1,000 mg of NR daily for eight weeks. Whole-blood NAD+ increased in the active groups, and the paper reported no significant adverse-event differences between groups. The study was funded by ChromaDex and disclosed author financial relationships. Its central questions concerned metabolism and tolerability, rather than whether participants became less fatigued or lived longer. ^[1]

Those details make the study useful without turning its highest arm into a recommended target. A larger chemical response is not a measurement of greater everyday benefit. Nor can eight weeks establish the consequences of every long-term use pattern.

A higher amount did not settle the benefit question

Dollerup and colleagues studied 40 men with obesity and insulin resistance, without diabetes, in a randomized placebo-controlled trial. Participants assigned NR received 1,000 mg twice daily for 12 weeks. The reported analysis did not find improvement in glucose tolerance, pancreatic hormone function or the measured incretin responses. ^[2]

That result does not prove every possible NR use is ineffective. It does show why arranging products from low to high milligrams is a poor substitute for examining outcomes. The experiment asked a defined metabolic question in a selected group. Its answer cannot be repaired by pointing to a different trial’s blood NAD+ percentage.

NMN provides a different example

A 10-week randomized trial in postmenopausal women with prediabetes and overweight or obesity tested 250 mg of NMN daily. It reported improved muscle insulin sensitivity and related signaling measures. The finding belongs to that population and intervention; it is not a head-to-head demonstration that 250 mg of NMN is equivalent or superior to a particular NR dose. ^[3]

The smaller number is not evidence of greater potency across all outcomes. Different molecules, participants and measurements can produce different answers without supplying a conversion rule between capsules.

Read the study amount with the study question

These are selected examples, not an exhaustive catalogue of every NAD-related trial. The amounts are included to make the comparison legible, not to provide instructions for taking them.

What a product label can actually resolve

Start with the named ingredient and the amount per serving, then check how many capsules make that serving. An advertised formula total may combine several ingredients. Paying for a bottle with more milligrams does not establish that it reproduces a trial, especially if the preparation, additional ingredients or route differ.

Consider a hypothetical product advertising a 600 mg blend without disclosing the amount of each component. It cannot be matched to a trial of 300 mg NR just by dividing the headline number. The missing ingredient quantities are the problem. A price-per-serving calculation becomes useful only after the product itself is clear.

Keep a trial protocol separate from your decision

A reader can compare label clarity, supply period and purchase terms without choosing a personal dose from this table. Ask a qualified clinician or pharmacist how the exact product fits your medical history and other medicines. A larger purchase or a higher amount should not be the automatic response to uncertainty.

For a comparison worth keeping, write down the ingredient, serving quantity, intended outcome and total purchase commitment on the same line. If a seller cites a study, match those entries to the paper. The useful conclusion may be that the formulation is clear while the hoped-for benefit remains unestablished. Those are two different judgments, and both belong in the decision.